- Home
- RCS vs CAPR Comparison
RCS vs CAPR Comparison
Compare RCS & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | CAPR |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.9M | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RCS | CAPR |
|---|---|---|
| Price | $6.73 | $27.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | 141.1K | ★ 5.8M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,130,509.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7,736.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.51 | $4.30 |
| 52 Week High | $6.31 | $40.37 |
Technical Indicators
Market Signals| Indicator | RCS | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 72.04 |
| Support Level | $6.65 | $25.60 |
| Resistance Level | $6.76 | $27.18 |
| Average True Range (ATR) | 0.12 | 3.35 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 26.02 | 61.78 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.